Issn Print: 0265-0215

Publication Date: 2006/06/01


Print

Prostaglandin I2 release following mesenteric traction during abdominal surgery is not COX-2 dependent: A-576

J. Hobbhahn; F. K. Kees; D. Lunz; S. Rath; M. Zelenka; M. Bucher

+ Author Information

Author Information: Department of Anaesthesiology; 2Department of Pharmacology, University of Regensburg, Germany

    loading  Checking for direct PDF access through Ovid

Excerpt

Background and Goal of Study: Mesenteric traction during abdominal surgery often is associated with the release of the vasodilatory prostaglandin-(PG)-I2 resulting in hemodynamic changes, decreased arterial pO2 and facial flushing (1). We determined the role of cyclooxygenase-2 in the release of (PG)-I2 induced by mesenteric traction during abdominal surgery.
Materials and Methods: In a prospective double-blind, randomized, placebocontrolled study, 40 patients electively scheduled for non-laparoscopic abdominal surgery, were pretreated with the cyclooxygenase-2 inhibitor parecoxib (n = 20) or placebo (n = 20). Plasma concentrations of the stable PGI2-metabolite 6-keto-PGF1α were compared between groups before injection of parecoxib (−40min), immediately before mesenteric traction (0min), and 5, 10, and 30 min thereafter. In addition, plasma concentrations of valdecoxib, the active metabolite of the prodrug parecoxib, were determined.
Results and Discussions: Plasma concentrations of 6-keto-PGF1α increased in both groups after mesenteric traction with no significant differences between both groups. Plasma concentrations of valdecoxib revealed therapeutic values.
Conclusion(s): PGI2 release following mesenteric traction is not mediated by cyclooxygenase-2. Therefore, pretreatment of patients with the cyclooxygenase-2 inhibitor parecoxib does not prevent the mesenteric traction syndrome.
    loading  Loading Related Articles